Michael G. Harrington

Best Publications

• Blood-Brain Barrier Breakdown in the Aging Human Hippocampus

  Axel Montagne;Samuel R. Barnes;Melanie D. Sweeney;Matthew R. Halliday

  2098
  Citations

• Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction.

  Daniel A Nation;Melanie D Sweeney;Axel Montagne;Abhay P Sagare

  1592
  Citations

• APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline

  Axel Montagne;Daniel A. Nation;Abhay P. Sagare;Giuseppe Barisano

  1170
  Citations

• The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies.

  Gary Hsich;Kimbra Kenney;Clarence J. Gibbs;Kelvin H. Lee

  836
  Citations

• Vascular dysfunction-The disregarded partner of Alzheimer's disease

  Melanie D. Sweeney;Axel Montagne;Abhay P. Sagare;Daniel A. Nation

  702
  Citations

• Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects.

  A. N. Fonteh;R. J. Harrington;A. Tsai;P. Liao

  292
  Citations

• No-reflow phenomenon in the heart and brain

  Robert A. Kloner;Robert A. Kloner;Kevin S. King;Michael G. Harrington;Michael G. Harrington

  216
  Citations

• Abnormal Proteins in the Cerebrospinal Fluid of Patients with Creutzfeldt–Jakob Disease

  Michael G. Harrington;Carl R. Merril;David M. Asher;D. Carleton Gajdusek

  201
  Citations

• REDUCED PLASMA DEHYDROEPIANDROSTERONE CONCENTRATIONS IN ALZHEIMER'S DISEASE

  Trey Sunderland;CarlR. Merril;MichaelG. Harrington;BrianA. Lawlor

  201
  Citations

• The significance of the incidental finding of basal ganglia calcification on computed tomography.

  M G Harrington;P Macpherson;W B McIntosh;B F Allam

  198
  Citations

• Protein analysis in human cerebrospinal fluid: Physiological aspects, current progress and future challenges.

  Andreas F. Hühmer;Roger G. Biringer;Heidi Amato;Alfred N. Fonteh

  193
  Citations

• Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel

  Claudio Babiloni;Xianghong Arakaki;Hamed Azami;Karim Bennys

  186
  Citations

• Association of Docosahexaenoic Acid Supplementation With Alzheimer Disease Stage in Apolipoprotein E ε4 Carriers: A Review

  Hussein N. Yassine;Meredith N. Braskie;Wendy J. Mack;Katherine J. Castor

  174
  Citations

• ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes.

  Varun Rawat;Shaowei Wang;Jian Sima;Roni Bar

  165
  Citations

• White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease.

  Lauren P. Klosinski;Jia Yao;Fei Yin;Alfred N. Fonteh

  160
  Citations

• Identification of Disease Markers in Human Cerebrospinal Fluid Using Lipidomic and Proteomic Methods

  Alfred N. Fonteh;Robert J. Harrington;Andreas F. Huhmer;Roger G. Biringer

  137
  Citations

• Human Cerebrospinal Fluid Fatty Acid Levels Differ between Supernatant Fluid and Brain-Derived Nanoparticle Fractions, and Are Altered in Alzheimer's Disease

  Alfred N. Fonteh;Matthew Cipolla;Jiarong Chiang;Xianghong Arakaki

  126
  Citations

• Executive Function Changes before Memory in Preclinical Alzheimer’s Pathology: A Prospective, Cross-Sectional, Case Control Study

  Michael G. Harrington;Jiarong Chiang;Janice M. Pogoda;Megan Gomez

  122
  Citations

• Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial

  Isabella C. Arellanes;Nicholas Choe;Victoria Solomon;Xulei He

  120
  Citations

• Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine

  S.D. Silberstein;D.W. Dodick;A.S. Lindblad;K. Holroyd

  106
  Citations

• The morphology and biochemistry of nanostructures provide evidence for synthesis and signaling functions in human cerebrospinal fluid

  Michael G. Harrington;Alfred N. Fonteh;Elena Oborina;Patricia Liao

  97
  Citations